Item 8.01. Other Events.
On
The Company is also eligible to receive up to an additional
If the tranche 2 warrants are fully exercised, under its current operating plan, the Company would expect its cash, cash equivalents and investments to fund the Company beyond the anticipated submission of its New Drug Application ("NDA") for CTP-543, which is expected in the first half of 2023.
Forward Looking Statements
Any statements in this Current Report on Form 8-K about the Company's future
expectations, plans and prospects, including, among others, statements about the
Company's expectations regarding the timing of regulatory filings and the
sufficiency of the Company's cash, cash equivalents and investments to fund its
operations, and any other statements containing the words "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will," "would" and
similar expressions, constitute forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a result
of various important factors, including: the uncertainties inherent in the
initiation, timing and design of future clinical trials, the availability and
timing of data from ongoing and future clinical trials and the results of such
trials, whether preliminary results, including safety profiles, from a clinical
trial will be predictive of the final results of that trial or whether results
of early clinical trials will be indicative of the results of later clinical
trials, expectations for the timing of the submission of an NDA, the
availability of regulatory approvals, the availability of funding sufficient for
the Company's foreseeable and unforeseeable operating expenses and capital
expenditure requirements, expectations with respect to the protection of the
Company's intellectual property afforded by its patents and other factors
discussed in the "Risk Factors" section of the Company's most recent Quarterly
Report on Form 10-Q filed with the
--------------------------------------------------------------------------------
© Edgar Online, source